Sonde Health Granted Foundational U.S. Patent for Use of Vocal Biomarkers in Health Assessments
12 Noviembre 2019 - 6:00AM
Business Wire
Patent includes core data security features and
diagnostic applications
Sonde Health, Inc., a leading company developing a voice-based
technology platform to measure health when a person speaks, today
announced that the United States Patent and Trademark Office issued
U.S. Patent No. 10,475,530, a foundational patent that covers
crucial aspects of Sonde’s vocal biomarker technology.
The patent covers the use of Sonde’s technology to capture,
analyze and utilize vocal biomarkers to potentially enable more
efficient and timely diagnosis and treatment of disease. As
affirmed in the patent, Sonde’s platform is designed to use these
vocal biomarkers – derived from analysis of short segments of
speech – to evaluate health and wellness and identify when an
individual should take additional screening tests or connect with a
medical professional. Accelerating disease diagnosis and cueing
treatment decisions in this manner could potentially enable people
to more quickly seek the care they need for conditions ranging from
depression to dementia to allergies. It also holds the potential to
significantly cut healthcare costs.
“This patent strengthens our mission to harness voice as a vital
sign so health and wellness can be quickly, accurately and
inexpensively monitored through snippets of speech as short as six
seconds in length,” said Jim Harper, Ph.D., co-founder and chief
operating officer of Sonde Health. “There is an incredibly broad
base of voice-capable consumer devices that are compatible with our
platform and enable us to prioritize patient data security as a
core feature. We are aggressively pursuing an intellectual property
portfolio that complements the technological advances being made by
our researchers in this exciting space.”
The patent announced today covers additional key aspects of
Sonde’s vocal biomarker technology, including its combination with
other contextual sensors, integration of voice-based biometrics for
user identity verification, and location-based control of vocal
biomarker technology activation. The patent also covers the
provision of ranked recommendations and scheduling of follow-up
care – such as a telehealth session – after voice-based analysis of
health and wellness status.
About Sonde Health Co-founded by PureTech Health (LSE:
PRTC), Sonde Health is developing a voice-based technology platform
to measure health when a person speaks. Sonde’s proprietary
technology is designed to sense and analyze subtle changes in the
voice to create a range of persistent brain, muscle, and
respiratory health measurements that provide a more complete
picture of health in just seconds. To date, Sonde has collected a
leading digital biobank containing millions of data points
comprizing voice samples and health metadata from over 20,000
individuals as part of the ongoing validation of its platform.
Sonde has broad intellectual property coverage worldwide, currently
owning or having exclusive rights to eight patent applications and
four issued patents in five families of patent filings.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112005178/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Tom Donovan +1 857 559
3397 tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024